105 related articles for article (PubMed ID: 17597835)
1. Rosiglitazone, an Agonist of PPARgamma, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2.
Han S; Zheng Y; Roman J
PPAR Res; 2007; 2007():29632. PubMed ID: 17597835
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways.
Han S; Roman J
Mol Cancer Ther; 2006 Feb; 5(2):430-7. PubMed ID: 16505118
[TBL] [Abstract][Full Text] [Related]
3. GW1929 inhibits α7 nAChR expression through PPARγ-independent activation of p38 MAPK and inactivation of PI3-K/mTOR: The role of Egr-1.
Hahn SS; Tang Q; Zheng F; Zhao S; Wu J
Cell Signal; 2014 Apr; 26(4):730-9. PubMed ID: 24412748
[TBL] [Abstract][Full Text] [Related]
4. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
5. Follicle-stimulating hormone increases tuberin phosphorylation and mammalian target of rapamycin signaling through an extracellular signal-regulated kinase-dependent pathway in rat granulosa cells.
Kayampilly PP; Menon KM
Endocrinology; 2007 Aug; 148(8):3950-7. PubMed ID: 17510244
[TBL] [Abstract][Full Text] [Related]
6. A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth.
Bruemmer D; Berger JP; Liu J; Kintscher U; Wakino S; Fleck E; Moller DE; Law RE
Eur J Pharmacol; 2003 Apr; 466(3):225-34. PubMed ID: 12694805
[TBL] [Abstract][Full Text] [Related]
7. Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2).
Rolfe M; McLeod LE; Pratt PF; Proud CG
Biochem J; 2005 Jun; 388(Pt 3):973-84. PubMed ID: 15757502
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.
Osman I; Segar L
Biochem Pharmacol; 2016 Feb; 101():54-70. PubMed ID: 26643070
[TBL] [Abstract][Full Text] [Related]
9. Heme oxygenase-1 induction by rosiglitazone via PKCα/AMPKα/p38 MAPKα/SIRT1/PPARγ pathway suppresses lipopolysaccharide-mediated pulmonary inflammation.
Cho RL; Lin WN; Wang CY; Yang CC; Hsiao LD; Lin CC; Yang CM
Biochem Pharmacol; 2018 Feb; 148():222-237. PubMed ID: 29309760
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
Liu C; Zhang Y; Yuan L; Fu L; Mei C
Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
12. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
[TBL] [Abstract][Full Text] [Related]
13. Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin.
Finlay GA; Thannickal VJ; Fanburg BL; Kwiatkowski DJ
Cancer Res; 2005 Dec; 65(23):10881-90. PubMed ID: 16322235
[TBL] [Abstract][Full Text] [Related]
14. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling.
Yuan Y; Zhang A; Huang S; Ding G; Chen R
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F393-402. PubMed ID: 21123490
[TBL] [Abstract][Full Text] [Related]
15. Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth.
Han S; Roman J
Biochem Biophys Res Commun; 2004 Feb; 314(4):1093-9. PubMed ID: 14751245
[TBL] [Abstract][Full Text] [Related]
16. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
17. Role of the TSC1-TSC2 complex in the integration of insulin and glucose signaling involved in pancreatic beta-cell proliferation.
Bartolomé A; Guillén C; Benito M
Endocrinology; 2010 Jul; 151(7):3084-94. PubMed ID: 20427478
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the Tuberous sclerosis complex 2 (TSC2) gene inhibits goat myoblasts proliferation and differentiation in understanding the underlying mechanism of muscle development.
Lyu M; Shalitana A; Luo J; He H; Sun S; Wang P
Gene; 2020 Oct; 757():144943. PubMed ID: 32652105
[TBL] [Abstract][Full Text] [Related]
19. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance.
Tencer L; Burgermeister E; Ebert MP; Liscovitch M
Anticancer Res; 2008; 28(2A):895-906. PubMed ID: 18507034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
